SRR817758
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- IL6_JAK_STAT3_SIGNALING+0.403
- INFLAMMATORY_RESPONSE+0.386
- KRAS_SIGNALING_DN+0.385
- PANCREAS_BETA_CELLS+0.360
- ALLOGRAFT_REJECTION+0.334
- COMPLEMENT+0.301
- KRAS_SIGNALING_UP+0.276
- MYOGENESIS+0.253
- ANGIOGENESIS+0.233
- COAGULATION+0.231
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.588
- MYC_TARGETS_V1-0.575
- MYC_TARGETS_V2-0.520
- DNA_REPAIR-0.504
- UNFOLDED_PROTEIN_RESPONSE-0.493
- E2F_TARGETS-0.423
- MTORC1_SIGNALING-0.404
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.395
- G2M_CHECKPOINT-0.386
- ADIPOGENESIS-0.366
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR607478 | GTEX | — | 0.968 |
| 2 | SRR1331289 | GTEX | — | 0.958 |
| 3 | SRR1362464 | GTEX | — | 0.953 |
| 4 | SRR1320012 | GTEX | — | 0.949 |
| 5 | SRR598894 | GTEX | — | 0.949 |
| 6 | SRR820292 | GTEX | — | 0.939 |
| 7 | MNG275 | — | — | 0.939 |
| 8 | SRR658645 | GTEX | — | 0.938 |
| 9 | SRR1487295 | GTEX | — | 0.938 |
| 10 | SRR1322419 | GTEX | — | 0.937 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| IL6_JAK_STAT3_SIGNALING | 0.403 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.386 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.385 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.360 | Cobimetinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.334 | Idelalisib | — uncovered |
| COMPLEMENT | 0.301 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.276 | Inavolisib | — uncovered |
| MYOGENESIS | 0.253 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.233 | Remibrutinib | — uncovered |
| COAGULATION | 0.231 | Binimetinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.228 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.200 | Temsirolimus | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.178 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.166 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.162 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.135 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.128 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.104 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.082 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.081 | Inavolisib | — uncovered |